FDA Approves New Indication for Antibiotic Vibativ

The FDA has granted a new indication for Theravance’s antibiotic Vibativ to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) when other treatments fail. The expanded use is only for HABP/VABP, also known as nosocomial pneumonia, caused by Staphylococcus aureus.
Washington Drug Letter